147 related articles for article (PubMed ID: 31495943)
1. A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease.
Kristiansen O; Vethe NT; Fagerland MW; Bergan S; Munkhaugen J; Husebye E
Br J Clin Pharmacol; 2019 Dec; 85(12):2878-2885. PubMed ID: 31495943
[TBL] [Abstract][Full Text] [Related]
2. A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry.
Vethe NT; Munkhaugen J; Andersen AM; Husebye E; Bergan S
Ther Drug Monit; 2019 Feb; 41(1):19-28. PubMed ID: 30633723
[TBL] [Abstract][Full Text] [Related]
3. Validation of a novel direct method to determine reduced adherence to atorvastatin therapy.
Pivoriunas J; Vethe NT; Husebye E; Fagerland MW; Bergan S; Kristiansen O; Prof JM; Sverre E
Eur Heart J Cardiovasc Pharmacother; 2024 Jan; ():. PubMed ID: 38196131
[TBL] [Abstract][Full Text] [Related]
4. The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease.
Kristiansen O; Sverre E; Peersen K; Fagerland MW; Gjertsen E; Gullestad L; Perk J; Dammen T; Husebye E; Vethe NT; Munkhaugen J
Atherosclerosis; 2021 Nov; 336():23-29. PubMed ID: 34610521
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetics-based approach to the monitoring of patient adherence to atorvastatin therapy.
Karvaly GB; Karádi I; Vincze I; Neely MN; Trojnár E; Prohászka Z; Imreh É; Vásárhelyi B; Zsáry A
Pharmacol Res Perspect; 2021 Oct; 9(5):e00856. PubMed ID: 34478238
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose.
Cestari RN; Rocha A; Marques MP; de Oliveira RDR; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1126-1127():121766. PubMed ID: 31450089
[TBL] [Abstract][Full Text] [Related]
7. Monitoring Simvastatin Adherence in Patients With Coronary Heart Disease: A Proof-of-Concept Study Based on Pharmacokinetic Measurements in Blood Plasma.
Vethe NT; Husebye E; Andersen AM; Bergan S; Kristiansen O; Fagerland MW; Munkhaugen J
Ther Drug Monit; 2022 Aug; 44(4):558-567. PubMed ID: 35482468
[TBL] [Abstract][Full Text] [Related]
8. Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy.
Schaffer AL; Buckley NA; Pearson SA
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1465-1473. PubMed ID: 29067759
[TBL] [Abstract][Full Text] [Related]
9. Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial.
Kulik A; Abreu AM; Boronat V; Ruel M
J Thorac Cardiovasc Surg; 2019 Jan; 157(1):151-161.e1. PubMed ID: 30122341
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a sensitive, simple, and rapid method for simultaneous quantitation of atorvastatin and its acid and lactone metabolites by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Macwan JS; Ionita IA; Dostalek M; Akhlaghi F
Anal Bioanal Chem; 2011 Apr; 400(2):423-33. PubMed ID: 21359569
[TBL] [Abstract][Full Text] [Related]
11. Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care.
Bermingham M; Hayden J; Dawkins I; Miwa S; Gibson D; McDonald K; Ledwidge M
Clin Ther; 2011 Sep; 33(9):1180-9. PubMed ID: 21840055
[TBL] [Abstract][Full Text] [Related]
12. Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial.
Lopes RD; de Barros E Silva PGM; de Andrade Jesuíno I; Santucci EV; Barbosa LM; Damiani LP; Nakagawa Santos RH; Laranjeira LN; Dall Orto FTC; Beraldo de Andrade P; de Castro Bienert IR; Alexander JH; Granger CB; Berwanger O
JAMA Cardiol; 2018 Nov; 3(11):1113-1118. PubMed ID: 30264159
[TBL] [Abstract][Full Text] [Related]
13. Sensitive, High-Throughput Liquid Chromatography-Tandem Mass Spectrometry Analysis of Atorvastatin and Its Pharmacologically Active Metabolites in Serum for Supporting Precision Pharmacotherapy.
Karvaly GB; Vincze I; Karádi I; Vásárhelyi B; Zsáry A
Molecules; 2021 Mar; 26(5):. PubMed ID: 33801290
[TBL] [Abstract][Full Text] [Related]
14. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JA; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2002 Oct; 90(7):689-96. PubMed ID: 12356379
[TBL] [Abstract][Full Text] [Related]
15. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
Athyros VG; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
Curr Med Res Opin; 2002; 18(4):220-8. PubMed ID: 12201623
[TBL] [Abstract][Full Text] [Related]
16. Statin-associated muscle symptoms in coronary patients: design of a randomized study.
Munkhaugen J; Vethe NT; Fagerland MW; Dammen T; Perk J; Gjertsen E; Otterstad JE; Gullestad L; Bergan S; Husebye E
Scand Cardiovasc J; 2019 Jun; 53(3):162-168. PubMed ID: 31030568
[No Abstract] [Full Text] [Related]
17. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
[TBL] [Abstract][Full Text] [Related]
18. New steps in acute coronary syndrome and antihyperlipidemic treatment: Determination of statins and metabolites by liquid chromatography tandem mass spectrometry.
Yaglioglu H; Eryavuz Onmaz D; Abusoglu S; Erdem K; Sivrikaya A; Abusoglu G; Unlu A
Biomed Chromatogr; 2022 Aug; 36(8):e5390. PubMed ID: 35487588
[TBL] [Abstract][Full Text] [Related]
19. The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control study.
Lauritzen T; Munkhaugen J; Bergan S; Peersen K; Svarstad AC; Andersen AM; Pahnke J; Husebye E; Vethe NT
Atheroscler Plus; 2024 Mar; 55():31-38. PubMed ID: 38293288
[TBL] [Abstract][Full Text] [Related]
20. Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Athyros VG; Mikhailidis DP; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
Curr Med Res Opin; 2002; 18(8):499-502. PubMed ID: 12564661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
